Placebo + RG1662
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Down Syndrome
Conditions
Down Syndrome
Trial Timeline
Nov 1, 2011 → Sep 1, 2013
NCT ID
NCT01436955About Placebo + RG1662
Placebo + RG1662 is a phase 1 stage product being developed by Roche for Down Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01436955. Target conditions include Down Syndrome.
What happened to similar drugs?
1 of 3 similar drugs in Down Syndrome were approved
Approved (1) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01436955 | Phase 1 | Completed |
Competing Products
13 competing products in Down Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg) | Yuhan | Phase 1 | 29 |
| Aricept (donepezil hydrochloride) + Aricept (donepezil hydrochloride) + Placebo | Eisai | Phase 3 | 32 |
| Aricept (Donepezil hydrochloride) + Placebo | Eisai | Phase 3 | 32 |
| Donepezil hydrochloride (Aricept) | Eisai | Phase 2 | 27 |
| E2020-Donepezil hydrochloride + E2020-Donepezil hydrochloride + Placebo | Eisai | Phase 2 | 35 |
| Donepezil HCl + Placebo | Eisai | Phase 2 | 35 |
| Donanemab + Placebo | Eli Lilly | Approved | 50 |
| Placebo + RG1662 + RG1662 | Roche | Phase 2 | 35 |
| Placebo + RO5186582 | Roche | Phase 2 | 27 |
| RG1662 + placebo | Roche | Phase 1 | 29 |
| ELND005 + Placebo | Elanco | Phase 2 | 32 |
| ACI-24 low dose + ACI-24 high dose + Placebo | AC Immune | Phase 1 | 19 |
| ACI-24 + Placebo | AC Immune | Phase 2 | 17 |